Why the study?
Does CI-1031 prolong time to occlusion and reduce thrombus mass in a rabbit veno-venous shunt model of thrombosis?
Population
Anesthetized rabbits in a veno-venous shunt model of thrombosis, and human plasma in vitro
Comparison
CI-1031 intravenously vs Vehicle
Design
Preclinical
Follow-up
140 min
Authors
Loading...
Supports preclinical antithrombotic activity of CI-1031; leaves open translation to human venous thrombosis trials.
Does CI-1031 prolong time to occlusion and reduce thrombus mass in a rabbit veno-venous shunt model of thrombosis?
CI-1031 demonstrates dose-dependent antithrombotic efficacy in a rabbit model, with plasma concentrations correlating well with PT and anti-FXa activity.
Chi et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: